The human coagulation system continuously generates very small quantities of Factor Xa and thrombin. Current evidence suggests that basal level activation of the hemostatic mechanism occurs via Factor VIIa-dependent activation of Factor X, but direct proof has not been available for the participation of tissue factor in this pathway. To examine this issue, we infused relatively high concentrations of recombinant Factor VIla ( -50 ugg/ kg body wt) into normal chimpanzees and observed significant increases in the plasma levels of Factor IX activation peptide, Factor X activation peptide, and prothrombin activation fragment F,12. Metabolic turnover studies with radiolabeled Factor IX activation peptide, Factor X activation peptide, and F1+2 indicate that elevated levels of the activation peptides are due to accelerated conversion of the three coagulation system zymogens into serine proteases. The administration of a potent monoclonal antibody to tissue factor, which immediately neutralizes function of the Factor VIla-tissue factor complex in vitro, abolishes the activation of Factor X and prothrombin mediated by the infused recombinant protein, and also suppresses basal level activation of Factor IX and Factor X. The above results suggest that recombinant Factor VIla functions as a prohemostatic agent by interacting with endogenous tissue factor sites, but definitive proof will require studies in hemophilic animals using relevant hemostatic endpoints. (J. Clin.
Introduction
The human coagulation mechanism is composed of intrinsic and extrinsic reaction cascades, which converge at the level of Factor X and lead through a final common pathway to the generation of thrombin and formation of fibrin (1, 2) . Previous in vitro investigations demonstrated that intrinsic cascade function involves the Factor XIIa-dependent activation of Factor XI, and the subsequent Factor XIa-dependent activation of Factor IX. However it has recently been shown that thrombin can activate Factor XI in the presence ofa negatively charged surface (3, 4) . Early in vitro studies revealed that the Factor VIIa-tissue factor (TF)' complex cannot only activate Factor X, but also Factor IX (5, 6) . Using specific immunoassays for activation peptides, we have shown in humans that Factor VII, but not Factor XI, is mainly responsible for Factor IX activation under basal conditions (7) . Indeed, Factor VIIdeficient patients exhibit drastically reduced plasma concentrations of Factor IX activation peptide (FIXP) and Factor X activation peptide (FXP), which are restored to normal levels by infusion of relatively low concentrations (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) ,g/kg body wt) of recombinant Factor VIIa (7) (8) (9) .
Although Factor VIIa at physiological concentrations possesses very little ability to directly activate Factor X in vitro ( 10) , there is currently no direct evidence that activation of this zymogen by Factor VIa in vivo requires association with TF. Patients with Factor VIII inhibitors have been infused with large amounts of recombinant Factor VIIa with beneficial effects on hemostasis (11) (12) (13) . Considerable doubt exists whether TF is required for the above response, and it has been demonstrated that a phospholipid surface alone is sufficient to promote activation ofFactor X by Factor VIIa ( 14-16). In the present communication, we infuse relatively high concentrations of recombinant Factor VIIa into normal chimpanzees and demonstrate accelerated activation ofFactor IX, Factor X, and prothrombin. The administration of a potent mAb directed against human TF to the animals inhibits the activation of Factor X and prothrombin by the infused recombinant protein, and also suppresses basal level activation ofFactor IX and Factor X.
Methods
Chimpanzees. Adult male chimpanzees (Pan troglodytes) were housed at the New York University Medical Center Laboratory for Experimental Medicine and Surgery in Primates (Tuxedo, NY) and the New Mexico Regional Primate Research Laboratories (Alamagordo, NM). The animals selected for study weighed between 52 and 62 kg, exhibited normal kidney as well as liver function, and had not participated in infectious disease investigations during the time period of the Factor VIIa infusions. The general anesthetics used in these investigations were either ketamine or halothane, and the length of the experiments did not exceed 6 h. In separate control experiments, no significant differences were observed between the two anesthetics with regard to the levels ofactivation peptides generated (data not shown). The study 1. Abbreviations used in thispaper: FIXP, Factor IX activation peptide; F,12, prothrombin activation fragment; FPA, fibrinopeptide; FXP, Factor X activation peptide; TF, tissue factor; TFPI, TF pathway inhibitor.
protocols were approved by the animal health and welfare committee of the primate centers and were conducted according to the guidelines of the American Physiological Society.
Blood collection and processing. Venous blood was obtained from the antecubital veins of chimpanzees by two syringe technique using 2 1-gauge butterfly needles. Blood samples for the FIXP and FXP RIAs were drawn into plastic syringes preloaded with the following anticoagulant: 38 mmol/liter citric acid, 75 mmol/liter sodium citrate, 136 mmol/liter dextrose, 6 mmol/liter EDTA, 6 mmol/liter adenosine, and 25 U/ml heparin. The ratio of anticoagulant to blood used was 0.2:1.0 (vol/vol). For the F,12 and fibrinopeptide A (FPA) assays, an anticoagulant containing a thrombin inhibitor, EDTA, and aprotinin was purchased from Byk-Sangtec (Dietzenbach, Germany); the ratio of anticoagulant to blood used was 0.1:0.9 (vol/vol). The measurements of coagulation factors, Factor VII/VIIa antigen levels, and cell counts were carried out on blood collected in sodium citrate at a final concentration of 3.8% (wt/vol). All plasma specimens were centrifuged at 4VC for 20 min at 1,600 g, and stored at -70'C until assayed.
Assays. Factor VII/VIIa antigen levels were determined with an enzyme-linked immunosorbent assay (Asserachrom VII; American Bioproducts Co., Parsippany, NJ). The FIXPs, FXPs, and were quantified with specific immunoassays as described previously (7, 8, 17, 18) . The FPA measurements were established by radioimmunoassay with a kit provided by Byk-Sangtec.
Chimpanzeeprotein purification. Chimpanzee Factor IX, Factor X, and prothrombin were isolated from barium chloride-adsorbed plasma by affinity chromatography using specific mAbs (7, 18) . The above products were also examined by nondenaturing gel electrophoresis, and were shown to be homogeneous with respect to size by the SDS gel electrophoretic system of Laemmli (20) . The individual vitamin Kdependent proteins purified from chimpanzee plasma migrated at the same rate as human Factor IX, human Factor X, and prothrombin, respectively. The levels of contaminating activation peptides in the Factor IX, Factor X, and prothrombin preparations as judged by immunoassays against the human activation fragment counterparts were undetectable, 1%, atd 0.1%, respectively, on a molar basis as compared to the zymogens. Human Factor IX, human Factor X, and prothrombin were obtained from Enzyme Research Laboratories, South Bend, IN, and were physically homogeneous as judged by nondenaturating gel electrophoresis. The human coagulation proteins were diluted in 0.05 M Tris-HCl, 0.10 M NaCl, pH 7.5, containing 4% (wt/vol) ovalbumin to concentrations comparable to the chimpanzee preparations. The chimpanzee and human proteins were then activated in vitro, and the levels of activation peptides determined. The Factor IX and Factor X preparations were incubated for 3 h at 370C with final concentrations of 5.7 nmol/liter to 50 nnmol/liter recombinant Factor VIla, 4.9 nmol/liter relipidated human brain tissue factor (Drs. Ronald Bach and Yale Nemerson, Mount Sinai Medical Center, New York), and 4.9 mmol/liter CaCl2. Similarly, prothrombin preparations were incubated for 60 min at 240C in I ml reaction mixtures containing 10 mM trifuging the blood samples at 1,600 gfor 1O min, the 1251/ '3'I counts in 0.5 ml of plasma were quantified in a Gamma 8000 Counting System (Beckman Instruments Inc., Irvine, CA). The plasma protein radioactivity determinations are described as a function of time by a two-exponential curve, CIe'rI + C2e r2t (22) . The fractional breakdown rate, kB, was calculated from (C, /r, + C2/r2)-' (22) .
Recombinant proteins and monoclonal antibodies. Human recombinant Factor VIIa (23) was obtained as a lyophilized powder from Novo Nordisk (Gentofte, Denmark) and was reconstituted in sterile water before use. The anti-TF mAb TF8-5G9, which blocks Factor X activation by the Factor VIIa-TF complex in vitro, was provided at a protein concentration of 5.5 mg/ml in PBS (24, 25) .
Statistical analysis. The within and between group differences were analyzed by ANOVA, and P values were calculated with NewmanKeul's test to correct for multiple comparisons (26) . P values below 0.05 were considered statistically significant.
Results
The immunoreactivities of chimpanzee FIXP, chimpanzee FXP, and chimpanzee F,+2 were compared with their respective human fragment homologues. This was accomplished by activating purified chimpanzee and human zymogens, which had been quantified by immunoassays using human proteins, and then measuring the levels of activation peptides using immunoassays directed against the human activation fragments. On a molar basis, the results obtained show that chimpanzee Factor IX, chimpanzee Factor X, and chimpanzee prothrombin were converted to their activated products at a level of 100, 61, and 100%, respectively, whereas human Factor IX, human Factor X, and human factor prothrombin were converted to their activated products at a level of 87, 75, and 91%, respectively, under identical reaction conditions. These data indicate that the immunoreactivities of chimpanzee and human zymogens and the respective activation peptides are virtually identical.
Given these observations, we used immunoassays previously developed to quantify human coagulation zymogen activation to measure the effects of recombinant human Factor Vlla on the hemostatic mechanism ofchimpanzees. The intravenous administration of 3 mg of human recombinant Factor VIla (-= 50 ,gg/kg body wt) to five chimpanzees produced at 5 plasma Factor VIla concentrations also was associated with an min an immediate increase in mean Factor VII/VIIa antigen increase in mean F1+2 levels of 2.2-fold at 2 h, which remained levels from 53% of normal±6.4 (SD) to 191%±21. The levels high at the termination of the experiments (Table III) . The only gradually returned towards baseline levels, and remained time-dependent changes in plasma FPA levels were virtually elevated at 88%±9.0 (SD) at S h. The augmentation of the identical to those of F,+2, rising from 8.8 nmol/liter to a peak plasma Factor VIIa measurements was associated with an averof 68.2 nmol/liter at 1 h, and remained elevated at 20.8 nmol/ age increase in FIXP and FXP of 1.6-fold at 30 min (Table I) liter at the end of the experiments (data not shown). It should and 3-fold at 15 min (Table II) , respectively. These elevations be noted that the highest concentrations of F1+2 as well as FPA gradually returned to baseline values at 4 h. The elevation in in chimpanzees were observed at 1-2 h, which were delayed as We then determined the involvement ofTF in Factor VIIainduced alterations ofcoagulation system activation by administering to three chimpanzees a single intravenous dose of 600 ,ug/kg of mAb TF8-5G9 just before infusing 3 mg of recombinant enzyme. The elevations of the plasma concentrations of FXP and F,12 induced by Factor VIIa were abolished (Tables II   and III) , but suppression ofthe augmented FIXP levels was not observed in two of the three animals (Table I) . We also examined the effect of the anti-TF mAb on the basal activity of the coagulation system. Two chimpanzees were administered mAb TF8-5G9 at a dose of 4 mg/kg body wt and two chimpanzees were infused with buffer without mAb. The plasma levels of FIXP, FXP, and F1,2 were determined initially and at varying intervals up to 24 h after mAb administration. The mean concentrations of FIXP and FXP decreased from 86.8 and 108 pmol/liter initially, to 41.9 and 66.4 pmol/liter at 6 h, and to 22.7 and 26.5 pmol/liter at 24 h, respectively, in the mAbtreated animals. In the control animals receiving buffer, the mean concentrations of FIXP and FXP were 202 and 158 pmol/liter initially, 200 and 177 pmol/liter at 6 h, and 170 and 121 pmol/liter at 24 h, respectively. These results suggest that neutralization of Factor VIIa-TF by the mAb suppresses basal level activation of Factor IX and Factor X, although a prolonged period of time is required for maximal effect. Interestingly, no downward trend was noted in plasma F,12 measurements (data not shown).
Discussion
Under physiologic conditions, the human coagulation system continuously generates small amounts of Factor Xa and thrombin (8, 18) . The current evidence suggests that this basal level activation ofthe hemostatic mechanism occurs via Factor VIIa, and the participation of TF, though implied, remains to be substantiated (7) (8) (9) . The present set of studies in chimpanzees attempts to resolve this issue. Firstly, we demonstrate that recombinant Factor VIla infusions ( 50,ug/kgbody wt) produce significant increases in the levels of FIXP, FXP, and F,1+2* Secondly, we provide evidence that recombinant Factor VIIainduced elevations in the levels of FXP and F,12 are due to accelerated conversion of the coagulation system zymogens into their respective serine proteases rather than altered metabolic behavior of the activation fragments. Thirdly, we show that neutralization of TF and Factor VIIa-TF complex by administration ofa specific mAb (TF8-5G9) abolishes the activation of Factor X and prothrombin by recombinant Factor VIIa. Fourthly, we demonstrate that infusions of this anti-TF mAb lead to a time-dependent reduction in the basal levels of FIXP and FXP.
The experimental results outlined above can be explained by hypothesizing that TF molecules on cell surfaces in chimpanzees are saturated with varying proportions ofFactor VII or Factor VIIa. The Factor VIIa-TF complex results from the proteolytic activation of Factor VII-TF by Factor Xa (27) , Factor IXa (28), or Factor VIIa-TF (29) . The resultant complexes initiate low level conversion of Factor IX and Factor X to active enzymes, the latter ofwhich is responsible for a major portion ofthe basal activity ofthe coagulation mechanism (9) . Upon infusion ofrecombinant Factor VIIa, increased amounts ofFactor VIIa vis a vis Factor VII associate with TF. Given that the Factor VIIa-TF complex, as compared with Factor VII-TF interaction product, exhibits 120-fold or greater procoagulant potency, the activation of Factor IX and Factor X is augmented (30, 31 ) .
The FIXP and FXP levels in chimpanzees reach apogees at 15-30 min, somewhat delayed in comparison to the almost immediate increases in plasma concentrations of recombinant Factor VIa. It is of interest to note that similar investigations conducted with lower doses of recombinant Factor VIIa (10-20 jig/kg body wt) in a severely Factor VII-deficient human with essentially no coagulant protein showed that production of FIXP and FXP takes place almost immediately, whereas virtually identical studies carried out with a Factor VII-deficient patient with a reasonable level of immunoreactive protein (17% of normal) revealed that generation of FIXP and FXP occurs with some time delay as described above (9) .
Thus, it appears that plasma Factor VII must be competitively displaced from some TF sites by recombinant Factor VIIa before activation of Factor IX and Factor X is observed. The elevations of FXP and FIXP levels in chimpanzees persist for -2 h, which cannot be explained by Factor VIIa-induced alterations in the metabolic behavior ofthe activation markers. Indeed, in the Factor VII-deficient patients who were infused with the recombinant protein, increased FXP and FIXP concentrations similarly occur over relatively prolonged periods of time (9) . These persistent elevations probably result from ongoing activation of the zymogens by Factor VIIa-TF complex which is only slowly neutralized by tissue factor pathway inhibitor (TFPI) (32) . The ambient plasma concentrations of TFPI average 2.5 nmol/liter (33) , which are about one fourth of the peak plasma levels of recombinant factor VIa achieved in our chimpanzee studies. Thus, normal plasma concentrations of TFPI may be insufficient to inhibit the levels of Factor VIIa-TF complex generated in our investigations. Alternatively, the requirement for TFPI to initially interact with Factor Xa followed by assembly with Factor VIIa-TF may diminish the rate of inhibition to permit the observed FIXP and FXP activation rates (34) . The elevations of F,12 as well as FPA in chimpanzees reach maximal values at 1-2 h, which are delayed as compared to the peak levels ofFXP at 15-30 min and remain raised for a longer period of time. The delayed generation of F,12 versus FXP and FIXP has also been observed in humans infused with recombinant Factor VIla (9), and again cannot result from altered metabolic behavior of this activation marker in the animals. We hypothesize that the above phenomena may be due to a gradual time-dependent loss of TFPI inhibitory action or a time dependent activation of cell surfaces such as platelets resulting in enhanced prothrombinase assembly and function (35) .
In two ofthe three chimpanzees that received anti-TF mAb before recombinant Factor VIa, suppression of the increased FIXP levels was not observed, but increased Factor Xa generation as well as prothrombin activation did not occur. It has recently been demonstrated that an antibody to TF (TF8-11 D 12), which is undoubtedly identical to TF8-5G9, also inhibits Factor IX activation and Factor VII autoactivation in addition to Factor X activation by the Factor VIIa-TF complex in vitro (36) . These antibodies do not interfere with Factor VIIa binding to TF, but rather appear to block the access of the macomolecular substrates to the enzyme's active site by steric hindrance (25, 36 Factor IXa by Factor VIIa-TF (37). Alternatively, it is conceivable that TF exists in a different conformation in vivo as compared to in vitro and the mAb is unable to suppress Factor VIIa-TF-dependent conversion of Factor IX because of the altered structure.
In the studies in which anti-TF mAb was administered alone, a marked decrease was noted in the basal levels of FIXP and FXP, which was maximal at 24 h. At present, we cannot explain the absence of a concordant decline in F1.2 concentrations. However, in Factor VII-deficient patients, our recombinant Factor VIIa studies indicate that the F1,2 level is not as sensitive as FIXP and FXP to alterations in Factor VIIa-TF activity. In these patients, infusion of the recombinant Factor VIla only induced two-to fourfold increases in F1,2 levels while the other two activation markers increased 10-20-fold.
Recombinant Factor VIla preparations are currently being evaluated for treating bleeding episodes in hemophiliac patients with circulating Factor VIII inhibitors (12, 13) . The above investigations demonstrate that the procoagulant effect ofthe recombinant protein requires interaction ofenzyme with endogenous TF and that modest but prolonged bursts ofcoagulation system activity occur after infusion. These observations suggest that recombinant Factor VIIa preparations should be cautiously used in situations where high levels ofTF expression are suspected to avoid excessive activation of the hemostatic mechanism that could lead to thrombotic complications.
The cellular site at which Factor VIIa interacts with TF has not been determined. The infused recombinant Factor VIa could have complexed with endothelial cell TF. However, histochemical and in situ hybridization studies ofhuman blood vessels fail to detect TF protein or TF mRNA in unperturbed endothelial cells, although TF protein has been observed on foam cells ofatherosclerotic plaques (38, 39) . It is possible that TF is constituitively or episodically expressed by endothelial cells and monocytes in quantities sufficient to maintain basal level coagulation activity, but too low to be readily detected. It seems unlikely that the occurrence ofatherosclerotic plaques in chimpanzees could be responsible for basal activity ofthe coagulation mechanism since such lesions are infrequent in animals used in our studies that receive vegetarian diets (40) . The infused recombinant Factor VIIa cannot readily be implicated in triggering synthesis of endothelial cell or monocyte TF. From in vitro studies, it is known that endotoxin as well as tumor necrosis factor stimulates biosynthesis of TF (41, 42) , but this is unlikely with recombinant Factor VIIa that is free of these mediators. The infused recombinant Factor VIIa could have reached subendothelial sites which has been documented with other large molecules under in vivo conditions (43) . Perivascular and intramural fibroblasts express TF (39) and extremely small quantities can be functionally identified on vascular subendothelium (44) .
In summary, we have demonstrated that the procoagulant response elicited by infusion of high dose recombinant Factor VIIa is dependent upon TF. The data suggest that the prohemostatic effect of the recombinant protein, observed in patients with Factor VIII inhibitors, necessitates the same interaction. However, our experiments were performed in chimpanzees, without a bleeding diathesis, that were not subjected to vascular trauma. At such sites, there could be excessive exposure of activated phospholipid membranes as well as TF. Thus definitive proof of the mechanism of action of recombinant Factor VIla will require comparisons of relevant hemostatic endpoints in hemophilic animals receiving treatment in the presence and absence of TF inhibition. The present data also indicate that basal level coagulation system activity is at least partially dependent upon the amounts of TF on biologic surfaces in contact with blood components. We have previously documented age dependent elevations in activation peptide markers, and speculate that this type ofbiochemical hypercoagulability could, in part, be due to increased biosynthesis of TF in vivo (45) .
